Apellis Pharmaceuticals (APLS) PT Lowered to $83 at UBS
Tweet
Share
E-mailGet Alerts APLS Hot Sheet
Price: $41.03 --0%
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Rating Summary:
6 Buy, 23 Hold, 1 Sell
Rating Trend:
Down
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 20
Join SI Premium – FREE
UBS analyst Eliana Merle lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $83.00 (from $85.00) while maintaining a Buy rating.
You May Also Be Interested In
- Nomura/Instinet Downgrades Brother Industries Ltd (6448:JP) to Neutral
- Daiseki Co Ltd (9793:JP) PT Lowered to JPY5,100 at Nomura/Instinet
- Target (TGT) PT Raised to $170 at DA Davidson Ahead of Q2 Earnings
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
